Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire•04/11/2026•07:03 ET
0
Key Highlights
- ➤Q3 RYTELO revenue $60.1 million, up 5% sequentially
- ➤2026 RYTELO revenue guidance maintained at mid-to-high end of $220 million-$240 million
- ➤2026 operating expense guidance lowered to $220 million-$230 million
- ➤European RYTELO launch initiated; Germany availability expected by year-end
- ➤IMpactMF Phase 3 trial discontinued after DMC saw unlikely overall-survival success
Expert Statements
Harout Semerjian, President and Chief Executive Officer of Geron
“Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S.”
Harout Semerjian, President and Chief Executive Officer of Geron
“Outside the U.S. there is a clear opportunity for us to serve more patients and create additional value by broadening RYTELO’s access. As such, we have initiated a gated commercial launch to bring RYTELO to targeted EU markets with availability in Germany expected by the end of the year. Expanding access to therapies, along with pursing opportunistic innovation, is a key part of building a leading hematology company.”
Achieved $60.1 million in RYTELO(®) (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026
Reiterated 2026 RYTELO net product revenue at the mid-to-high end of the $220 million to $240 million range; lowered 2026 total operating expenses range to $220 million to $230 million
Get started
Create a free account to read the full story.